Arkell, Thomas R.
Lintzeris, Nicholas
Kevin, Richard C.
Ramaekers, Johannes G.
Vandrey, Ryan
Irwin, Christopher
Haber, Paul S.
McGregor, Iain S. http://orcid.org/0000-0002-9307-7159
Funding for this research was provided by:
The Lambert Initiative for Cannabinoid Therapeutics (N/A)
Article History
Received: 17 January 2019
Accepted: 9 April 2019
First Online: 1 May 2019
Compliance with ethical standards
:
: All participants gave written informed consent and all procedures were approved by the Sydney Local Health District (RPAH Zone) Human Research Ethics Committee.
: Nicholas Lintzeris has received funding for sponsored research studies from Camurus and has provided consultancies for Indivior and Mundipharma for unrelated work. Ryan Vandrey has received consulting fees from Zynerba Pharmaceuticals, Battelle Memorial Institute, and Canopy Health Innovations Inc. and has received compensation for being on the advisory boards for Insys Therapeutics, Brain Solutions Inc., and The Realm of Caring Foundation. Paul Haber has received research funding from Camurus, and has provided consultancies for Indivior, Abbvie, and Gilead for unrelated work. Iain McGregor acts as a consultant to Kinoxis Therapeutics and is an inventor on several patents relating to novel cannabinoid therapeutics. The other authors have no conflicts of interest to disclose.